On March 25, 2025, Acrivon Therapeutics reported a preliminary cash balance of approximately $184.6 million as of December 31, 2024, and shared interim clinical data showing promising results for their drug ACR-368 in endometrial cancer patients. The company is deprioritizing ovarian and bladder cancers to focus on ACR-368 for endometrial cancer, which has a potential market of about 27,000 patients annually in the U.S.